Cause specific survival, freedom of recurrence, disease free and overall survival of thymic carcinomas with a CDKN2A (Supplementary Fig. S1) or TP53 (Supplementary Fig. S2) gene alteration (mutation and/or deletion) did not differ from wild-type cases. This evidence concerns the gene TP53 and thymic carcinoma.